ライフサイエンスコーパス: alfa

1 ional therapeutic approaches (eg, interferon-alfa).

2 ly glycosylated protein therapeutic (Epoetin Alfa).

3 uring dose reduction or switch to agalsidase-alfa.

4 mild adverse events unrelated to sebelipase alfa.

5 REAT) among patients assigned to darbepoetin alfa.

6 risk of stroke was doubled with darbepoetin alfa.

7 h lower doses or were switched to agalsidase-alfa.

8 ved four once-weekly infusions of sebelipase alfa (0.35, 1, or 3 mg.kg(-1) ) before transitioning to

9 the Acute Leukemia French Association 0702 (ALFA-0702) trial, MRD evaluation was available in 152 pa

10 2010 for CIN lesions used topical interferon alfa 1 million IU/ml drops 4 times daily and retinoic ac

11 r (150 mg once daily, orally), peginterferon alfa 2a (180 mug once weekly, subcutaneous injection) or

12 Simeprevir once daily with peginterferon alfa 2a and ribavirin shortens therapy in treatment-naiv

13 Pegylated interferon (peginterferon) alfa 2a or 2b plus ribavirin regimens were the standard

14 inhibitor versus placebo, plus peginterferon alfa 2a or 2b plus ribavirin was assessed in treatment-n

15 for 12 weeks, followed by just peginterferon alfa 2a or 2b plus ribavirin.

16 placebo (once daily, orally), peginterferon alfa 2a or 2b, plus ribavirin (placebo group) for 12 wee

17 dition of simeprevir to either peginterferon alfa 2a or peginterferon alfa 2b plus ribavirin improved

18 irin for 12 weeks, followed by peginterferon alfa 2a plus ribavirin (placebo group).

19 irin for 12 weeks, followed by peginterferon alfa 2a plus ribavirin (simeprevir group), or placebo or

20 50 mg once daily, orally) plus peginterferon alfa 2a plus ribavirin for 12 weeks, followed by peginte

21 group), or placebo orally plus peginterferon alfa 2a plus ribavirin for 12 weeks, followed by peginte

22 S3/4A protease inhibitor, plus peginterferon alfa 2a plus ribavirin were assessed in treatment-naive

23 event profiles associated with peginterferon alfa 2a plus ribavirin.

24 virin was superior to placebo, peginterferon alfa 2a, and ribavirin (SVR12 in 210 [80%] patients of 2

25 Treatment with simeprevir, peginterferon alfa 2a, and ribavirin was superior to placebo, peginter

26 All patients received peg-IFN alfa-2a (180 microg/week) plus RBV (1000-1200 mg/day) fo

27 eneration protease inhibitor), peginterferon alfa-2a (40 KD), and ribavirin in these patients.

28 nts received mericitabine plus peginterferon alfa-2a (40KD)/ribavirin were analyzed by population and

29 were randomly assigned to receive either PEG alfa-2a (PEG-2a; 180 mug/1.73 m(2) body surface area, su

30 ir (SOF), ribavirin (RBV) and peg-interferon-alfa-2a (peg-IFN-alfa-2a) as well as the combination of

31 utaneous treatment with pegylated interferon-alfa-2a (Peg-IFNalfa-2a) 180 mug/wk, or albIFN 900 or 12

32 vir in combination with pegylated interferon alfa-2a (peginterferon) and ribavirin in non-cirrhotic t

33 crog/kg/week or 1 microg/kg/week, or peg-IFN alfa-2a 180 microg/week plus RBV.

34 ek (for arm B) of pegylated (Peg) interferon alfa-2a added to their current ART regimen.

35 to 1) by minimisation to receive interferon alfa-2a alone or combination therapy with interferon alf

36 were randomly assigned to receive interferon alfa-2a and 504 to receive combined treatment.

37 atients treated for 48 weeks with either PEG-alfa-2a and adefovir (ADV) or either drug alone in the H

38 U/mL) were treated with pegylated interferon alfa-2a and adefovir for 48 weeks.

39 and safety of pegylated interferon (peg-IFN) alfa-2a and peg-IFN alfa-2b plus ribavirin (RBV) in chil

40 (Group A, 11 patients) or with peginterferon alfa-2a and ribavirin (Group B, 10 patients) for 24 week

41 tients) or in combination with peginterferon alfa-2a and ribavirin (group B, 10 patients) for 24 week

42 vir in combination with pegylated interferon alfa-2a and ribavirin (Peg-IFN/RBV) for 15 days (TPR; n

43 d 2:1:1 to receive 48 weeks of peginterferon alfa-2a and ribavirin (PegIFN/RBV) in combination with f

44 to receive 24 weeks of pegylated interferon alfa-2a and ribavirin (PegIFN/RBV) in combination with p

45 200 mg once daily) plus pegylated interferon alfa-2a and ribavirin (PegIFNalpha-2a and RBV) for 4 wee

46 therapy with telaprevir alone, peginterferon alfa-2a and ribavirin (PR), or all 3 drugs (TPR) in trea

47 atients were then treated with peginterferon alfa-2a and ribavirin alone for 12 weeks if their level

48 weeks followed by 36 weeks of peginterferon alfa-2a and ribavirin alone.

49 responders with simeprevir and peginterferon alfa-2a and ribavirin and telaprevir and peginterferon a

50 virologic response (SVR) after peginterferon alfa-2a and ribavirin combination therapy in these patie

51 iving telaprevir combined with peginterferon alfa-2a and ribavirin for 12 weeks (T12PR group), follow

52 nce a day) in combination with peginterferon alfa-2a and ribavirin for 12 weeks followed by 36 weeks

53 y or 750 mg every 8 hours plus peginterferon alfa-2a and ribavirin for 12 weeks; patients were then t

54 ) who received sofosbuvir plus peginterferon alfa-2a and ribavirin for 8 weeks had a sustained virolo

55 or 12 weeks or sofosbuvir plus peginterferon alfa-2a and ribavirin for 8 weeks.

56 non-inferior to telaprevir and peginterferon alfa-2a and ribavirin for SVR12 (54% [203/379] vs 55% [2

57 eek regimen of sofosbuvir plus peginterferon alfa-2a and ribavirin in 327 patients with HCV genotype

58 Peginterferon alfa-2a and ribavirin therapy provides good HCV SVR dura

59 All patients received pegylated interferon alfa-2a and ribavirin therapy.

60 d ribavirin and telaprevir and peginterferon alfa-2a and ribavirin treatment, respectively.

61 t least one previous course of peginterferon alfa-2a and ribavirin treatment.

62 Simeprevir and peginterferon alfa-2a and ribavirin was non-inferior to telaprevir and

63 Simeprevir once a day with peginterferon alfa-2a and ribavirin was well tolerated in HCV genotype

64 very 12 hours) or placebo plus peginterferon alfa-2a and ribavirin, followed by peginterferon alfa-2a

65 clatasvir, in combination with peginterferon alfa-2a and ribavirin, is a well tolerated and effective

66 -2a and ribavirin, followed by peginterferon alfa-2a and ribavirin.

67 n placebo received 48 weeks of peginterferon alfa-2a and ribavirin.

68 treatment intensification with peginterferon alfa-2a and ribavirin.

69 iral agents were combined with peginterferon alfa-2a and ribavirin.

70 of placebo, each combined with peginterferon alfa-2a and ribavirin.

71 evir, each in combination with peginterferon alfa-2a and ribavirin.

72 duction is needed, even though pegylated IFN-alfa-2a and ruxolitinib might be useful in particular se

73 th RBV at 800 to 1400 mg/day, or (3) PEG-IFN alfa-2a at 180 microg/week with RBV at 1000 to 1200 mg/d

74 dose of 750 mg every 8 hours, peginterferon alfa-2a at a dose of 180 mug per week, and ribavirin at

75 INTERPRETATION: Pegylated interferon alfa-2a can induce durable haematological and molecular

76 Peginterferon alfa-2a could be an effective therapy for extensive or t

77 nal groups included 360 mug/wk peginterferon alfa-2a for 12 weeks then 180 mug/wk peginterferon alfa-

78 a for 12 weeks then 180 mug/wk peginterferon alfa-2a for 36 weeks plus 1200 mg/day ribavirin (group C

79 of these groups also received peginterferon alfa-2a for 4, 8, or 12 weeks.

80 Peg-interferon alfa-2a immunotherapy resulted in control of HIV replica

81 fficacy of REP 2139 and pegylated interferon alfa-2a in patients with chronic HBV and hepatitis D vir

82 Pegylated interferon alfa-2a induced haematological (66 [80%] of 83 patients)

83 Pegylated interferon alfa-2a is an immunomodulatory agent used to treat polyc

84 At week 12 of Peg-interferon alfa-2a monotherapy, viral suppression was observed in 9

85 nd 180 mug subcutaneous pegylated interferon alfa-2a once per week for 15 weeks, then monotherapy wit

86 onotherapy with 180 mug pegylated interferon alfa-2a once per week for 33 weeks.

87 Clinical trials examining peg-IFN alfa-2a or peg-IFN alfa-2b plus RBV among persons ages 3

88 ombination treatment of SOF, RBV and peg-IFN-alfa-2a or SOF and RBV.

89 immediate vs delayed treatment with peg-IFN alfa-2a plus RBV in participants with recent injection d

90 elihood of SVR than was pegylated interferon alfa-2a plus ribavirin (absolute difference, 8 percentag

91 plus ribavirin for 12 weeks or peginterferon alfa-2a plus ribavirin for 24 weeks.

92 nfection who received peginterferon (PEG-IN) alfa-2a plus ribavirin therapy for up to 48 weeks.

93 -week combination therapy with peginterferon alfa-2a plus ribavirin.

94 drugs treated with directly observed peg-IFN alfa-2a plus self-administered RBV, SVR is comparable to

95 ctly observed pegylated interferon (peg-IFN) alfa-2a plus self-administered ribavirin (RBV) for the t

96 the 4 groups or between pooled peginterferon alfa-2a regimens (A + B vs C + D: odds ratio [OR], 1.08;

97 : Combined REP 2139 and pegylated interferon alfa-2a therapy is safe, well tolerated, and establishes

98 nitial starting dose of pegylated interferon alfa-2a was 450 mug subcutaneously once per week, but wa

99 eks, ART was interrupted, and Peg-interferon alfa-2a was continued for up to 12 weeks (the primary en

100 Pegylated interferon alfa-2a was well tolerated and exhibited statistically s

101 in (RBV) and peg-interferon-alfa-2a (peg-IFN-alfa-2a) as well as the combination of SOF and RBV for t

102 The combination of danoprevir, peginterferon alfa-2a, and ribavirin leads to high rates of SVR in pat

103 alone or combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil.

104 The strength of peginterferon alfa-2a-induced IFIG response significantly correlated w

105 ential prognostic indicator in peginterferon alfa-2a-treated patients with HIV infection.

106 ore the introduction of pegylated interferon alfa-2a.

107 posi sarcoma were treated with peginterferon alfa-2a.

108 were treated for 12 weeks with peginterferon alfa-2a.

109 150 mg once daily) with pegylated interferon alfa-2a/ribavirin (peg-IFN/RBV) for 12 weeks.

110 nrolling patients treated with peginterferon alfa-2a/ribavirin (PEG/RBV) with or without TVL or BOC.

111 NS3-4A protease inhibitor) and peginterferon alfa-2a/ribavirin (PR) in patients with genotype 1 chron

112 treated with mericitabine plus peginterferon alfa-2a/ribavirin in PROPEL and JUMP-C, virologic breakt

113 ed with a total of 48 weeks of peginterferon alfa-2a/ribavirin.

114 = 58 in the final analysis) or peginterferon alfa 2b (1.5 mcg/kg/wk), ribavirin (1000-1200 mg/day), a

115 ither peginterferon alfa 2a or peginterferon alfa 2b plus ribavirin improved SVR in treatment-naive p

116 l cimetidine (15% vs 5%), topical interferon alfa-2b (0% vs 1%), cryotherapy (0% vs 3%), photodynamic

117 ith adjuvant topical or injection interferon alfa-2b (38% vs 15%).

118 High-dose interferon alfa-2b (HDI) has emerged as a potentially effective adj

119 High-dose interferon alfa-2b (HDI) was administered concurrently, including i

120 second-line therapy, he received interferon alfa-2b (IFN--2b) 2.7 MU daily, which he tolerated well.

121 were randomly assigned to receive interferon alfa-2b (IFN-alpha-2b) 20 MIU/m(2) intravenously (IV) da

122 survival (PFS) of bevacizumab or interferon alfa-2b (IFN-alpha-2b) added to octreotide among patient

123 , cisplatin, vinblastine, interleukin-2, IFN alfa-2b (IFN-alpha-2b) and granulocyte colony-stimulatin

124 aintenance therapy with pegylated interferon alfa-2b (IFN-alpha-2b) in patients whose osteosarcoma sh

125 Adjuvant pegylated interferon alfa-2b (PEG-IFN-alpha-2b) was approved for treatment of

126 with variable-duration pegylated interferon alfa-2b (PEG-IFN-alpha2b) and RBV.

127 Boceprevir (BOC) added to peginterferon alfa-2b (PegIFN) and ribavirin (RBV) significantly incre

128 py with boceprevir plus pegylated interferon alfa-2b (peginterferon) and ribavirin, which increases r

129 were treated for up to 48 weeks with peg-IFN alfa-2b 1.5 microg/kg/week or 1 microg/kg/week, or peg-I

130 e randomly assigned to receive peginterferon alfa-2b 1.5 mug/kg plus ribavirin 800-1400 mg daily for

131 e combination of tremelimumab and interferon alfa-2b acting via different and possibly synergistic me

132 y offer a superior alternative to interferon alfa-2b alone in treating CIN.

133 eriod compared with studies using interferon alfa-2b alone.

134 eve that combination treatment of interferon alfa-2b and retinoic acid may offer a superior alternati

135 ly for 48 weeks (PR48; n=104); peginterferon alfa-2b and ribavirin daily for 4 weeks, followed by peg

136 In all three groups, peginterferon alfa-2b and ribavirin were administered for 4 weeks (the

137 tease inhibitor, when added to peginterferon alfa-2b and ribavirin.

138 ising efficacy and safety of ropeginterferon alfa-2b and support the development of the drug in a ran

139 g that already low levels of ropeginterferon alfa-2b are sufficient to induce significant hematologic

140 rin (RBV) at 800 to 1400 mg/day, (2) PEG-IFN alfa-2b at 1.0 microg/kg/week with RBV at 800 to 1400 mg

141 following arms: (1) peginterferon (PEG-IFN) alfa-2b at 1.5 microg/kg/week with ribavirin (RBV) at 80

142 The unique feature of ropeginterferon alfa-2b is a longer elimination half-life, which allows

143 pical all-trans retinoic acid and interferon alfa-2b may act synergistically.

144 were normalized by treatment with interferon alfa-2b or after expression of wild-type DOCK2.

145 trials examining peg-IFN alfa-2a or peg-IFN alfa-2b plus RBV among persons ages 3-18 years with HCV

146 ted interferon (peg-IFN) alfa-2a and peg-IFN alfa-2b plus ribavirin (RBV) in children and adolescents

147 Dual therapy with pegylated interferon alfa-2b plus ribavirin was associated with a lower likel

148 nt oral cimetidine and/or topical interferon alfa-2b provide satisfactory tumor control.

149 evaluating the role of high-dose interferon alfa-2b therapy (HDI) or completion lymph node dissectio

150 ment of topical retinoic acid and interferon alfa-2b was effective in treating lesions with minimal s

151 eks, and lower doses of pegylated interferon alfa-2b were less effective than standard doses (2 to 4

152 cimetidine, topical or injection interferon alfa-2b, and photodynamic therapy.

153 daily for 4 weeks, followed by peginterferon alfa-2b, ribavirin, and boceprevir 800 mg three times a

154 4 weeks (PR4/PRB44; n=103); or peginterferon alfa-2b, ribavirin, and boceprevir three times a day for

155 eron (IFN) alpha-2b isoform, ropeginterferon alfa-2b.

156 nd for low-dose radioiodine plus thyrotropin alfa (84.3%) versus high-dose radioiodine plus thyroid h

157 %) or high-dose radioiodine plus thyrotropin alfa (90.2%).

158 Olipudase alfa, a recombinant form of human ASM, is being develope

159 Talactoferrin alfa, a recombinant form of human lactoferrin, has simil

160 multi-modal neonatal brain MR images, named ALFA (Accurate Learning with Few Atlases).

161 A decade after drotrecogin alfa (activated) (DAA) was released on the market worldw

162 nt human activated protein C, or drotrecogin alfa (activated) (DrotAA), for the treatment of patients

163 ortality was reduced by 18% with drotrecogin alfa (activated) compared with controls (relative risk 0

164 mental and analytical studies of drotrecogin alfa (activated) in adults with severe sepsis until Jan

165 lity for single-group studies of drotrecogin alfa (activated) was 41% (95% CI 35-48), and was higher

166 The serious bleeding rate with drotrecogin alfa (activated) was 5.6% (4.5-6.9), which was higher th

167 Drotrecogin alfa (activated) was approved for use in severe sepsis i

168 Real-life use of drotrecrogin alfa (activated) was associated with significant reducti

169 ssion showed greater benefits of drotrecogin alfa (activated) with increasing control mortality (p=0.

170 risk of bleeding associated with drotrecogin alfa (activated).

171 f enzyme-replacement therapy with sebelipase alfa (administered intravenously at a dose of 1 mg per k

172 AlfA, an ALP that pushes plasmids apart in Bacillus, rel

173 These data establish that sebelipase alfa, an investigational enzyme replacement, in patients

174 nduced production of different ratios of IFN alfa and beta, resulting in different autophagic respons

175 ith hydroxyurea as first-line and interferon-alfa and busulfan as second-line drugs of choice.

176 ard of care has been subcutaneous interferon alfa and oral ribavirin for 24-72 weeks.

177 ) at 6 months did not differ between epoetin alfa and placebo, but declines in stroke volume (-5+/-8

178 boceprevir or telaprevir with peginterferon-alfa and ribavirin for the treatment of patients infecte

179 Because pegylated interferon alfa and ribavirin remain a key part of the treatment re

180 typical of those expected from peginterferon alfa and ribavirin therapy.

181 uccessful eradication of HCV with interferon alfa and ribavirin was shown to improve some of these ex

182 laprevir, combined with pegylated interferon alfa and ribavirin, is an efficacious approach to treat

183 rst 12 weeks of treatment with pegylated IFN-alfa and ribavirin, the time period used to define the e

184 infection include pegylated interferon (IFN)-alfa and ribavirin.

185 n patients treated with pegylated interferon-alfa and ribavirin.

186 pg/mL for EPOzeta, 30 pg/mL for darbepoetin alfa, and 80 pg/mL for C.E.R.A.

187 d the recombinant forms EPOzeta, darbepoetin alfa, and C.E.R.A., from human urine is described, emplo

188 eeks (n = 199); or sofosbuvir, peginterferon-alfa, and ribavirin for 12 weeks (n = 197).

189 he investigational factor Xa decoy andexanet alfa, and the synthetic small molecule ciraparantag.

190 with CHIKV in the presence of RBV and/or IFN alfa, and viral production was quantified by plaque assa

191 Andexanet alfa (andexanet) is a recombinant modified human factor

192 a stroke, 101/2012 (5.0%) in the darbepoetin alfa arm and 53/2026 (2.6%) in the placebo arm (hazard r

193 udies illustrate the promise of RBV plus IFN alfa as a potential therapeutic strategy for the treatme

194 clinically relevant regimens of RBV and IFN alfa as combination therapy.

195 ties of ribavirin (RBV) and interferon (IFN) alfa as monotherapy and combination therapy against chik

196 bazine, interleukin-2 (IL-2), and interferon alfa as part of a clinical trial, he developed headaches

197 In the HFIM system, RBV plus IFN alfa at clinical exposures resulted in a 2.1-log10 decre

198 Interferon alfa-based regimens used to treat recurrent hepatitis C

199 Free AlfB breaks up AlfA bundles and promotes filament turnover.

200 As ALFA can learn from partially labelled datasets, it can

201 a suggest that short-term treatment with IFN alfa combined with RBV decreases HIV expression, in part

202 ALFA could also be applied to other imaging modalities a

203 Treatment with darbepoetin alfa did not improve clinical outcomes in patients with

204 lobin level, platelet count, and darbepoetin alfa dose did not differ between those with and without

205 After stimulation with thyrotropin alfa, dosimetry with iodine-124 positron-emission tomogr

206 tenance therapy with rituximab or interferon alfa, each given until progression.

207 phase and a single dose (60,000 U of epoetin alfa) efficacy phase; the Reduction of Infarct Expansion

208 AlfA elongates unidirectionally and is not dynamically u

209 rity study to evaluate the impact of epoetin alfa (EPO) on tumor outcomes when used to treat anemia i

210 Epoetin alfa (EPO) robustly induced bone marrow erythroferrone (

211 28B(rs12979860), serum 25OH-vitamin D, serum alfa-fetoprotein (AFP)) were performed on a cohort of 20

212 evated serum human chorionic gonadotropin or alfa-fetoprotein concentrations that matched Internation

213 , patients' human chorionic gonadotropin and alfa-fetoprotein concentrations were measured at day 18-

214 decline in human chorionic gonadotropin and alfa-fetoprotein continued BEP (Fav-BEP group) for 3 add

215 rosome complex that nucleates and stabilizes AlfA filaments.

216 t week (first CMR) was larger in the epoetin alfa group (19.9% LV mass; 95% CI, 14.0-25.7% LV mass) t

217 d in 153 patients (13.5%) in the darbepoetin alfa group and 114 patients (10.0%) in the placebo group

218 red in 42 patients (3.7%) in the darbepoetin alfa group and 31 patients (2.7%) in the placebo group (

219 of 1136 patients (50.7%) in the darbepoetin alfa group and 565 of 1142 patients (49.5%) in the place

220 in 11 of 36 patients (31%) in the sebelipase alfa group and in 2 of 30 (7%) in the placebo group (P=0

221 e group (P=0.007) and 23% in the thyrotropin alfa group versus 30% in the group undergoing thyroid ho

222 g the high dose and 87.1% in the thyrotropin alfa group versus 86.7% in the group undergoing thyroid

223 al {CI}, 13.3-18.2% LV mass] for the epoetin alfa group vs 15.0% LV mass [95% CI, 12.6-17.3% LV mass]

224 acebo group (hazard ratio in the darbepoetin alfa group, 1.01; 95% confidence interval, 0.90 to 1.13;

225 o had a poor initial response to darbepoetin alfa had a lower average hemoglobin level at 12 weeks an

226 s, hevein-like peptides, snakins, cyclotide, alfa-hairpinins and LTPs.

227 after 4 years, 58%, vs. 29% with interferon alfa; hazard ratio for progression or death, 0.55; 95% c

228 reatment of HDV is with pegylated interferon alfa; however, response rates are poor.

229 epatitis C virus (HCV) infection, interferon alfa (IFN-alpha) alters expression of IFN-stimulated gen

230 epatitis C virus (HCV) infection, interferon alfa (IFN-alpha) alters expression of IFN-stimulated gen

231 olony-stimulating factor (G-CSF), interferon alfa (IFN-alpha), macrophage inflammatory protein 1alpha

232 treatment, 38% were treated with interferon alfa (IFNalpha)-based therapies, and 33% received nucleo

233 ndings do not support the use of darbepoetin alfa in these patients.

234 e 2-fold increase in stroke with darbepoetin alfa in TREAT could not be attributed to any baseline ch

235 nd ribavirin, with and without peginterferon-alfa, in treatment-experienced patients with cirrhosis a

236 e of patients with spontaneous or interferon alfa-induced resolution of acute or chronic infections,

237 edicted FEV1, and chronic therapies (dornase alfa, inhaled antibiotics, inhaled and oral corticostero

238 Talactoferrin alfa is a recombinant form of the human glycoprotein, la

239 Switching to agalsidase-alfa is safe, but microalbuminuria may progress and Fabr

240 espite receiving higher doses of darbepoetin alfa (median dose, 232 mug vs. 167 mug; P<0.001).

241 ety of the recombinant human LAL, sebelipase alfa, nine patients received four once-weekly infusions

242 of stroke included assignment to darbepoetin alfa (odds ratio 2.1; 95% confidence interval, 1.5-2.9),

243 We evaluated the effects of darbepoetin alfa on clinical outcomes in patients with systolic hear

244 However, the short-term impact of IFN alfa on persistent HIV and its effects on immune activat

245 fect of 5 years of treatment with agalsidase alfa or agalsidase beta in 12 consecutive patients age 7

246 signed to treatment with intravenous epoetin alfa or matching saline placebo administered within 4 ho

247 and anemia randomized to receive darbepoetin alfa or placebo.

248 each in combination with either thyrotropin alfa or thyroid hormone withdrawal before ablation.

249 r recombinant human thyrotropin (thyrotropin alfa) or thyroid hormone withdrawal.

250 tomatitis virus, a synthetic HCV genome, IFN alfa, or IFN beta.

251 ALFA outperformed the eleven compared methods providing

252 survival rate, 87%, vs. 63% with interferon alfa; P=0.005).

253 6 patients treated with pegylated interferon alfa (Peg-IFN) and adefovir.

254 previr, when given with pegylated interferon alfa (Peg-IFN) and ribavirin (RBV), result in a much hig

255 viral agent telaprevir, pegylated-interferon alfa (Peg-IFN), and ribavirin (RBV) significantly increa

256 is B respond to treatment with peginterferon alfa (PEG-IFN).

257 Pegylated interferon alfa (PEG-IFNalpha) is effective in only 25%-30% of pati

258 remained stagnant, with pegylated interferon alfa (PegIFN) plus ribavirin (RBV; PegIFN/RBV) entrenche

259 cal studies demonstrated pegvorhyaluronidase alfa (PEGPH20) degrades HA, thereby increasing drug deli

260 been randomly assigned to receive interferon alfa plus cytarabine (65.6%) and the short duration of t

261 ase to receive either imatinib or interferon alfa plus cytarabine.

262 Long-term treatment with interferon (IFN) alfa plus ribavirin decreases the proviral human immunod

263 evir to pegylated interferon (peginterferon) alfa plus ribavirin has improved sustained virological r

264 Combined with peginterferon-alfa plus ribavirin they offer genotype-1 infected patie

265 adverse events associated with peginterferon alfa plus ribavirin.

266 eligible for and intolerant of peginterferon alfa plus ribavirin.

267 ve; previous non-responders to peginterferon alfa plus ribavirin; or medically ineligible for, previo

268 In patients assigned to darbepoetin alfa, postrandomization systolic and diastolic blood pre

269 in NPs were then functionalised with dornase alfa (recombinant human deoxyribonuclease I, DNase), dem

270 inant human activated protein C (drotrecogin alfa) reduced mortality in patients with severe sepsis a

271 be used to mitigate the risk of darbepoetin alfa-related stroke.

272 Interferon alfa remains the central treatment for chronic hepatitis

273 Treatment with epoetin alfa resulted in significant increases in hemoglobin (P<

274 telaprevir or boceprevir plus peginterferon alfa-ribavirin).

275 2 (100-800 mg/day) plus pegylated interferon alfa/ribavirin (peg-IFN/RBV) during a phase 2 trial.

276 ding a long-lived reduction in alglucosidase alfa-specific ADA.

277 Infants received 200 mg/kg of poractant alfa (surfactant) or air after randomization.

278 up, n=29), or switch to 0.2 mg/kg agalsidase-alfa (switch group) and were followed prospectively for

279 ining sunitinib, bevacizumab plus interferon-alfa, temsirolimus, or cytokines.

280 rt, of the 125 patients who received epoetin alfa, the composite outcome of death, MI, stroke, or ste

281 Sebelipase alfa therapy resulted in a reduction in multiple disease

282 The administration of the ESA epoetin alfa to critically ill trauma patients has been associat

283 Administration of epoetin alfa to older adult patients with heart failure and a pr

284 per deciliter) to receive either darbepoetin alfa (to achieve a hemoglobin target of 13 g per decilit

285 mucous hyperpigmentations during interferon alfa treatment have been reported, but they are consider

286 seven patients receiving ongoing sebelipase alfa treatment in LAL-CL04, the mean +/- standard deviat

287 econdary hyperpigmentation during interferon alfa treatment occurs as an adverse event in 21% of pati

288 rs aimed to evaluate the efficacy of epoetin alfa treatment on the outcome of OHCA patients in a phas

289 Interferon-alfa treatment-experienced patients (n = 42) were random

290 32 [99%]), irrespective of the peginterferon alfa used.

291 Low-dose radioiodine plus thyrotropin alfa was as effective as high-dose radioiodine, with a l

292 The neutral effect of darbepoetin alfa was consistent across all prespecified subgroups.

293 Sebelipase alfa was well tolerated, with mostly mild adverse events

294 or the increased risk related to darbepoetin alfa, we performed a nested case-control analysis (1:10

295 RBV and IFN alfa were effective against CHIKV as monotherapy at supr

296 However, RBV and IFN alfa were highly synergistic for antiviral effect when a

297 ls that have been tolerized to alglucosidase alfa with methotrexate can transfer tolerance to naive h

298 safety of recombinant adenovirus interferon alfa with Syn3 (rAd-IFNalpha/Syn3), a replication-defici

299 e PCI, a single intravenous bolus of epoetin alfa within 4 hours of PCI did not reduce infarct size a

300 at treating anemia with subcutaneous epoetin alfa would be associated with reverse ventricular remode

301 a standard clinical regimen of RBV plus IFN alfa would inhibit CHIKV burden by 2.5 log10 following 2